The Non-Steroidal Farnesoid X Receptor (FXR) Agonist GS-9674 Improves Liver Biochemistry and Decreases Serum Bile Acids in Patients with Primary Sclerosing Cholangitis (PSC): A Phase 2, Randomized, Placebo-Controlled Trial
Journal article published in 2018 by
Michael H. Trauner,
Aliya Gulamhusein,
Bilal Hameed,
Stephen H. Caldwell,
Mitchell L. Shiffman,
Charles S. Landis,
Bertus Eksteen,
Kosh Agarwal 
,
Andrew Joseph Muir,
Simon M. Rushbrook,
Tuan Nguyen,
Xiaomin Lu,
Georgia Li,
Chuhan Chung,
Mani Subramanian
and other authors.
,
Andrew Joseph Muir,
Simon M. Rushbrook,
Tuan Nguyen,
Xiaomin Lu,
Georgia Li,
Chuhan Chung,
Mani Subramanian
and other authors.
